Putting the patient first: new modalities of manufacturing for cell therapy though real-time process changes

Cell & Gene Therapy Insights 2021; 7(11), 1867–1882

10.18609/cgti.2021.282

Published: 10 March 2022
Innovator Insight
Ben Wang, Kan Wang, Chelsea White

When manufacturing cell therapies, how can you build a process that accounts for the numerous possibilities of product composition, and the health of the patient from whom the therapy will be manufactured? In this article new modalities for cell therapy manufacturing that change the current paradigm of a fixed manufacturing process, in order to enable a more personalized approach and improve clinical outcomes, are explored.